Phase 3 Failure Aftershock... $300 Million Vanished from Nasdaq Biotech in a Day

Immunovant Inc. (NASDAQ: IMVT) closed at $26.99 per share on the 27th, down 5.7%, cutting its market capitalization by about $300 million to roughly $5.5 billion (approximately KRW 7 trillion). Trading volume spiked to around 1.7 million shares, as both profit-taking and disappointment-driven selling emerged amid heightened volatility.

Earlier this month, news that two Phase 3 trials of its thyroid eye disease therapy batoclimab missed primary endpoints led investors to price in increased risk for its lead pipeline. Adding to the pressure on short-term sentiment, disclosures on April 23 revealed that the company’s CFO and CTO sold several hundred thousand dollars’ worth of shares.

Immunovant is a clinical-stage immunology biotech developing autoimmune disease treatments—including thyroid eye disease, myasthenia gravis and chronic inflammatory demyelinating polyneuropathy—centered on its FcRn-targeted candidate IMVT-1402 and batoclimab. Parent company Roivant Sciences bolstered its long-term growth bet last December by acquiring an additional stake valued at about $350 million (KRW 500–600 billion), positioning the success of IMVT-1402 as a key driver of corporate value going forward.